Clinical trial
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic…
NCT00118261 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00118261 |
|---|---|
| Title | Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer |
| Official title | A Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin |
| Enrollment | 17 |
| Start date | Mar 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Jul 11, 2005 |
| Last update posted | Sep 3, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: